Process: Provide long-term appreciation through passive exposure to primarily large-cap US equities. Through O’Shaughnessy’s Canvas Custom Index platform, the investment process uses a risk-based ...

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...

Annexon (NASDAQ:ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026 ...

Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four treatment arms, and primary efficacy endpoint while explaining the rationale ...

A new open-access review proposes attacking both the upstream enzymes of the bacterial shikimate pathway and the ...

A new commentary argues that touch-induced analgesia arises from a dynamic brain-spinal cord network in which supraspinal and ...

HURST, Texas — Keith Castello spends a lot of time praying about available real estate. Driving in his white pickup under a glaring Texas sun, the classical Christian school administrator points out ...

Insight Enterprises (NASDAQ: NSIT) today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, reinforcing Insight's position as a provider of AI solutions for ...

Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, ...